Trends and sociodemographic disparities in the circulatory disease prevalence in the United States: An analysis of the National Health Interview Survey database (2019–2022) Authors: Farah Yasmin, Abdul Moeed, Muhammad Ahmed Ali Fahim, Hafsah Alim Ur Rahman, Maryam Shaharyar, Afia Salman, Muhammad Sohaib Asghar, M Chadi Alraies Published: 2025 ABSTRACT AbstractBackgroundCirculatory diseases are a leading cause of mortality in the United States (U.S). This study examined trends and disparities in the prevalence of angina pectoris (AP), coronary heart disease (CHD), myocardial infarction (MI), and hypertension (HTN) among U.S. adults from 2019 to 2022.Materials and methodsThe National Health Interview Survey (NHIS) database from the Centers for Disease Control and Prevention (CDC) was analyzed using Joinpoint regression analysis to determine annual percentage changes (APCs) and prevalence percentages with 95% confidence intervals. The data was stratified by year, gender, age, race, veteran status, social vulnerability index (SVI), employment status, nativity, census region, and metropolitan statistical area (MSA) status.ResultsPatients aged 75 and older had the highest incidence rates of all circulatory diseases. HTN was most prevalent, remaining stable at around 27% from 2019 to 2022. Males had a higher prevalence than females, remaining stable overall. CHD rates increased from 4.6% in 2019 to 4.9% in 2020, with males again showing higher rates and both genders showing significant increases over time. White individuals had the highest CHD incidence (5.4% in 2022), with the West having the lowest (3.8% in 2022). AP prevalence was stable but higher in males throughout the study period with insignificant changes in either gender. MI prevalence remained stable from 3.1% in 2019 to 3.0% in 2022, with White individuals and the South region demonstrating the highest MI prevalence (3.3% in 2022 for both) respectively.ConclusionThe rising prevalence of certain circulatory diseases requires immediate intervention. Targeted actions should prioritize high-risk groups, including males, older adults, veterans, and the unemployed, to reduce the burden of these diseases and improve cardiovascular health among U.S. adults.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12872-025-05139-z.Keywords: Circulatory disease prevalence, National health interview survey, U.S. adults, Health disparities Introduction Cardiovascular diseases are referred to as a heterogeneous group of cardiac and circulatory system-related disorders leading to significant mortality and morbidity [1, 2]. Atherosclerotic cardiovascular disease, arterial hypertension (HTN), and coronary heart disease (CHD) remain the leading cardiovascular diseases [1, 3]. Atherosclerotic cardiovascular disease may lead to cardiac ischemia, manifesting as angina pectoris (AP) and myocardial infarction (MI) [4, 5]. A decline was observed in cardiovascular mortality trends in the United States during 2010–2019, however, this decline reversed, and the excessive mortality trends persisted during 2020–2022 [6]. Worsened risk factor control and persistent racial and ethnic disparities are the major contributors to such trends [7, 8]. According to the Centers for Disease Control and Prevention (CDC) report, approximately 695,000 heart disease patients died in the year 2021 [9]. There has been a 9% rise in cardiovascular disease mortality rates during 2020–2022 compared to 2010–2019 [6]. The prevalence of coronary heart disease (CHD) has increased to 4.9% in 2022 and is subject to significant racial and age-related disparities [9]. Moreover, the national prevalence of HTN is 49.64% being significantly greater in non-Hispanic Blacks, older individuals, and obese persons [10]. In the U.S. population, 7.9 million individuals have suffered heart attacks, and 9 million have experienced angina pectoris. The overall prevalence of MI in adults aged 20 and older is around 3.1%, according to a 2010 study by Roger et al. [11]. These findings underscore not only the increasing burden of major cardiovascular diseases but also the need to further explore how social determinants influence disease distribution. While previous studies in the medical literature have examined the incidence and mortality trends of individual cardiovascular diseases, there is a notable lack of recent analyses that explore multiple cardiovascular conditions concurrently, particularly in relation to racial and ethnic disparities, geographic variation, and gender differences. Unlike traditional population-based research, which tends to focus broadly on prevalence and mortality, this study offers a more current, post-COVID-19 snapshot that reflects recent shifts in healthcare dynamics. We conducted this study to explore the trends and disparities in the prevalence of myocardial infarction (MI), angina pectoris (AP), coronary heart disease (CHD), and hypertension (HTN) among U.S. adults aged 18 years and older between 2019 and 2022. The findings have the potential to inform public health strategies, guide resource allocation, and help identify high-risk populations. Materials and methods Data source and study population This study was performed using data from the CDC’s National Center for Health Statistics (NCHS) Interactive Summary Health Statistics for Adults database based on the National Health Interview Survey (NHIS) [12]. Annual NHIS data from 2019 to 2022 were utilized. The selection of the 2019–2022 study period was intentional and grounded in the unique public health context it represents. Specifically, 2019 was included as a pre-pandemic baseline, allowing us to compare disparities in circulatory disease prevalence before and during the COVID-19 pandemic (2020–2022). This demarcation is critical for identifying whether pandemic-related disruptions were associated with shifts in disease burden or the widening or narrowing of disparities. Our study population included noninstitutionalized US civilians aged > 18 years across all 50 states and the District of Columbia and excluded active-duty military personnel, civilians living on military bases, and individuals in institutional settings such as nursing homes or correctional facilities. NHIS utilizes a nationally representative, cross-sectional design based on a multistage, geographically clustered sampling strategy to minimize selection bias. Data is collected using computer-assisted personal interviews conducted in the respondent’s household. Telephone-based interviews were utilized in instances where an interview was incomplete on the initial visit and during the COVID-19 pandemic. Each participant was interviewed only once per year with no follow-up. Institutional Review Board approval was not required for this study as all data were publicly available [13]. Variables and measures We investigated the prevalence of four circulatory diseases available from thedatabase i.e., diagnosed HTN, CHD, AP, and MI. To define AP, CHD and MI respondents were asked if they had ever been told by a doctor or other health professional that they had angina/AP, CHD or a heart attack/MI respectively. To ascertain diagnosed HTN, respondents were asked if they had ever been told by a doctor or other health professional that they had HTN/high blood pressure, and if so, if they had been told on two or more different visits. Respondents who answered affirmatively were asked if they had been told they had HTN/high blood pressure during the past year. Respondents who had HTN were also asked if they were taking prescribed medication for high blood pressure. Respondents had to have been taking those medications or had HTN/high blood pressure during the past year to be classified as having diagnosed hypertension. Additionally, outcome data were stratified by year, gender, age, race, geography (metropolitan statistical area (MSA), census regions, and sociodemographic factors, including social vulnerability index (SVI), employment status, veteran status, and nativity. Social vulnerability refers to the demographic and socioeconomic factors (such as poverty, lack of access to transportation, and crowded housing) that adversely affect communities that encounter hazards and other community-level stressors. The United States Census Bureau divides the country into four census regions—Northeast, Midwest, South, and West—each comprising several states with shared geographic and demographic characteristics. All variables used were based on information obtained from the Sample Adult component of the NHIS [13]. For this study, we analyzed self-reported diagnoses of coronary heart disease (CHD), angina pectoris (AP), myocardial infarction (MI), and hypertension (HTN) as separate conditions based on how they are coded and reported in the National Health Interview Survey (NHIS). While AP and MI are commonly considered clinical manifestations of coronary heart disease (CHD), they were treated independently to allow for a more detailed examination of prevalence trends and subgroup disparities. We acknowledge that some overlap may exist between these categories due to comorbid conditions or classification practices within the NHIS dataset. Statistical analysis We calculated the annual prevalence of each outcome across all variables, presenting results as crude/unadjusted percentages with their corresponding two-sided 95% CI. The two-sided 95% confidence intervals were calculated using the Clopper-Pearson method adapted for complex surveys by Korn and Graubard [14]. The Joinpoint Regression Program (Version 5.0.2, National Cancer Institute) which employs the Monte Carlo Permutation method was utilized to determine the annual percent change (APC) with 95% CI in prevalence across the demographic subgroups. This software identifies significant variations in prevalence percentages over time by fitting log-linear regression models where temporal shifts occurred, and considers the APCs to be increasing or decreasing if the slope of the regression line describing the change in prevalence significantly differs from zero, based on 2-tailed t-testing. Importantly, APC in this context does not assume a uniformly linear trend but instead captures potential stepwise or abrupt changes, such as those expected due to the onset or progression of the COVID-19 pandemic. Model fit and the number of join points were selected based on the Bayesian Information Criterion (BIC). Statistical significance was defined as P < 0.05. Weighting and variance estimation To ensure national representativeness, NHIS data were weighted to account for complex survey design, clustered sampling, unequal probabilities of selection, and nonresponse. Additionally, to ensure that data maintains representativeness across age, sex, race, and other key demographic variables, these weights were calibrated to align with the U.S. Census Bureau population projections and the American Community Survey 1-year estimates. To adjust for complex survey design, variance estimates were calculated using Taylor Series Linearization, providing estimates of variability of the outcomes included [13]. Results The NHIS surveyed a total of 120,698 adults, survey respondents declined marginally over the years from 31,997 in 2019 to 27,651 in 2020. The ratio of male and female respondents remained relatively consistent over the 4 years analyzed, with 54% male and 46% female. Respondents were generally younger, below 65 years of age. The majority of participants surveyed each year were White, followed by Hispanic or Latino, Black, and Asian individuals. The white proportion decreased slightly over the years, from 68.5% in 2019 to 66.0% in 2022. When stratifying by census regions, the majority of respondents were residents of the South, followed by the West, Midwest, and Northeast. Demographic characteristics are provided in Table 1. Table 1Annual demographic characteristics of the surveyed population2019202020212022Total31,997 (100%)31,568 (100%)29,482 (100%)27,651 (100%)Male14,733 (46.0%)14,521 (46.0%)13,378 (45.4%)12,598 (45.6%)Female17,261 (54.0%)17,045 (54.0%)16,102 (54.6%)15,050 (54.4%)Age 18–4412,024 (37.6%)10,884 (34.5%)10,927 (37.1%)10,030 (36.3%)Age 45–6410,597 (33.1%)10,589 (33.5%)9,592 (32.5%)8,786 (31.8%)Age 65–745,322 (16.6%)5,664 (17.9%)5,016 (17.0%)5,014 (18.1%)≥Age 754,054 (12.7%)4,431 (14.0%)3,947 (13.4%)3,821 (13.8%)Hispanic or Latino4,152 (13.0%)3,833 (12.1%)4,081 (13.8%)3,943 (14.3%)Black or African American, single race3,483 (10.9%)3,201 (10.1%)3,160 (10.7%)3,112 (11.3%)White, single-race21,915 (68.5%)22,090 (70.0%)19,658 (66.7%)18,242 (66.0%)Asian, single race1,648 (5.2%)1,682 (5.3%)1,810 (6.1%)1,663 (6.0%)Northeast5,410 (16.9%)5,619 (17.8%)4,775 (16.2%)4,590 (16.6%)Midwest7,104 (22.2%)7,175 (22.7%)6,327 (21.5%)6,033 (21.8%)South11,676 (36.5%)10,908 (34.6%)10,731 (36.4%)10,171 (36.8%)West7,807 (24.4%)7,866 (24.9%)7,649 (25.9%)6,857 (24.8%) Annual demographic characteristics of the surveyed population Diagnosed hypertension Prevalence of diagnosed hypertension by gender and age Among the four diseases analyzed, HTN had the highest prevalence, remaining relatively steady from 27% (95% CI 26.4 to 27.7) in 2019 to 27.2% (95% CI 26.5 to 27.8) in 2022 (APC: 0.3341%, 95% CI −0.8540 to 1.5536%). The prevalence of HTN among males increased significantly from 27.2% (95% CI 26.3 to 28.1) in 2019 to 27.9% (95% CI 27.0 to 28.8) in 2022 (APC: 1.0234%, 95% CI 0.2471–1.7943%). Females presented a nonsignificant decrease from 26.9% (95% CI 26.1 to 27.8) to 26.5% (95% CI 25.7 to 27.3) across the study period (APC: −0.4865%, 95% CI −3.0964 to 2.2713%). Prevalence increased significantly with age, peaking at 64.5% (95% CI 62.1 to 66.3) for those 75 and older in 2019 compared with just 7.4% (95% CI 6.8 to 7.9) for those aged between 18 and 44 years (Figs. 1 and 2, Supplementary Tables 1, 2). Prevalence of diagnosed hypertension for adults 18 and over in the United States 2019–2022 Annual percentage change of diagnosed hypertension for adults 18 and over in the United States 2019–2022 Prevalence of diagnosed hypertension by race When analyzing race, Black or African Americans consistently had the highest prevalence, showing little variation with rates peaking at 34.4% (95% CI 32.4 to 36.4) in 2022, followed by Whites, increasing from 27.1% (95% CI 26.4 to 27.8) to 27.4% (95% CI 26.7 to 28.2). Descendants of Asian and Hispanic ethnicity had the lowest prevalence rates of HTN, with Asian adults witnessing an increase from 19.7% (95% CI 17.4 to 22.1) to 21.1% (95% CI 18.8 to 23.5) across the study period. Moreover, Hispanic or Latino populations showed a slight decrease from 20.2% (95% CI 18.7 to 21.8) to 19.7% (95% CI 18.3 to 21.1). Prevalence of diagnosed hypertension by geography Taking urbanization into account, prevalence varied by metropolitan statistical areas (MSA), and non-MSA areas showed a noticeably higher prevalence, with a decrease from 34.5% (95% CI 32.7 to 36.3) to 33.4% (95% CI 31.5 to 35.4) across the study period. Small and Large MSAs had considerably lower rates, with prevalence increasing in small MSAs from 28.2% (95% CI 27.0 to 29.5) to 29.1% (95% CI 27.9 to 30.3), while remaining consistent in Large MSAs (24.4% in 2019 to 24.6% in 2022). Among census regions, the South had the greatest incidence, showing steady rates with prevalence peaking at 30.2% (95% CI 29.1 to 31.2) in 2021. Rates were comparable in the Northeast and Midwest, showing little variation from 27.1% (95% CI 25.7 to 28.5) to 27.0% (95% CI 25.5 to 28.6) for the Northeast; however, a small uptick was noted in the Midwest from 26.3% (95% CI 24.9 to 27.7) to 27.1% (95% CI 25.9 to 28.3). Additionally, the West had the lowest rates, staying more or less consistent between 22.9% (95% CI 21.7 to 24.2) and 22.5% (95% CI 21.4 to 23.8) throughout the study period. Prevalence of diagnosed hypertension by socio-vulnerability, employment and veteran status Higher social vulnerability correlated with higher HTN prevalence, decreasing from 30.1% (95% CI 28.8 to 31.5) to 27.8% (95% CI 26.7 to 28.9). Low and little-to-no social vulnerability populations had the lowest incidence of HTN, with rates for individuals with low social vulnerability showing a notable rise from 25.9% (95% CI 24.6 to 27.4) to 25.3% (95% CI 23.7 to 27.0) while prevalence remained consistent 25.9% (95% CI 24.6 to 27.4) and 25.3% (95% CI 23.7 to 27.0) for the no social vulnerability cohort. Individuals with a medium level of social vulnerability had consistent rates of HTN prevalence from 27.9% (95% CI 26.8 to 29.0) to 27.7% (95% CI 26.5 to 29.0). The unemployed consistently had more than double the rates of HTN, with 42.9% (95% CI 41.9 to 44.0) as compared to 18.2% (95% CI 17.5 to 18.9) in 2022 for the employed. Veterans’ prevalence decreased from 44.9% (95% CI 42.8 to 47.0) in 2019 to 43.9% (95% CI 41.5 to 46.3) in 2022, still substantially higher than the 25.4% (95% CI 24.8 to 26.1) to 25.8% (95% CI 25.2 to 26.5) for non-veterans. Foreign-born individuals consistently reported lower prevalence rates ranging from 23.4% (95% CI 21.9 to 24.9) to 24.1% (95% CI 22.6 to 25.6) between 2019 and 2022 compared to a uniform 27.9% (95% CI 27.2 to 28.6) for U.S.-born individuals. Coronary heart disease Prevalence of coronary heart disease by gender and age The prevalence of CHD among U.S. adults aged 18 and over remained fairly stable at around 4.6% (95% CI 4.3 to 4.9) in 2019 and 2020, with a slight increase to 4.9% (95% CI 4.7 to 5.2) in 2021 and 2022. Analyzing APCs showed no significant change (APC: 2.5%; 95% CI 0.5–5.8%). The narrow confidence intervals over these four years indicate consistent survey methodologies and stable disease rates. Males consistently showed higher CHD prevalence than females, increasing from 5.9% (95% CI 5.5 to 6.3) in 2019 to 6.4% (95% CI 5.9 to 6.8) in 2022. Female prevalence was lower, ranging from 3.4% (95% CI 3.1 to 3.7) in 2019 to 3.6% (95% CI 3.3 to 3.9) in 2022. Both genders witnessed significant increases in annual trend analysis (male APC 3.1%, 95% CI 1.45–4.85% vs. female APC 2.0%, 95% CI 0.46–3.59%). Prevalence rates increased significantly with age, peaking at 20.0% (95% CI 18.5 to 21.6) for those 75 and older in 2020 and slightly declining to 19.7% (95% CI 18.2 to 21.3) in 2022. In comparison, a negligible incidence of CHD was present in individuals aged between 18 and 44 years (0.5% in 2022) (Table 1; Figs. 3 and 4, Supplementary Table 1). Prevalence of coronary artery disease for adults 18 and over in the United States 2019–2022 Annual percentage change of coronary artery disease for adults 18 and over in the United States 2019–2022 Prevalence of coronary heart disease by race White adults had the highest incidence of CHD, with rates showing a minor increase from 5.0% (95% CI 4.7 to 5.3) in 2019 to 5.4% (95% CI 5.1 to 5.8) in 2022. They were followed by Black or African Americans, who also showed an increase from 4.4% (95% CI 3.7 to 5.2) in 2019 to 5.0% (95% CI 4.1 to 6.0) in 2021 but an overall decrease to 4.2% (95% CI 3.5 to 5.0) by 2022. Asians and Hispanics again had the lowest prevalence rates. Notably, rates saw an uptick from 2019 to 2020 for Asians, rising from 2.8% (95% CI 1.9 to 3.8) to 3.8% (95% CI 2.7 to 5.1). A more negligible increase was evident in the Hispanic population from 2.8% (95% CI 2.3 to 3.5) to 3.0% (95% CI 2.5 to 3.6) in 2022. Prevalence of coronary heart disease by geography Prevalence varied by MSA, with rates in non-MSA areas rising substantially from 6.1% (95% CI 5.3 to 6.9) in 2019 to 7.5% (95% CI 6.6 to 8.4) in 2022. In comparison, Small MSAs showed 5.0% (95% CI 4.5 to 5.5) in 2019 and 5.2% (95% CI 4.8 to 5.7) in 2022, while Large MSAs reported 4.0% (95% CI 3.7 to 4.4) in 2019 and 4.1% (95% CI 3.8 to 4.5) in 2022. Residents of the South had the highest prevalence, peaking at 5.7% (95% CI 5.2 to 6.3) in 2021. This was followed by the Northeast and Midwest. The Northeast saw an increase from 5.0% (95% CI 4.4 to 5.8) in 2019 to 5.5% (95% CI 4.8 to 6.3) in 2022, as did the Midwest from 4.6% (95% CI 4.1 to 5.2) to 5.1% (95% CI 4.6 to 5.7). The West had the lowest rates, ranging from 3.6% (95% CI 3.1 to 4.1) to 3.8% (95% CI 3.3 to 4.3). Prevalence of coronary heart disease by socio-vulnerability, employment and veteran status Comparable rates were noted for CHD respondents when categorized according to the CDC’s SVI. Briefly, higher social vulnerability populations noted a decrease from 5.2% (95% CI 4.6 to 5.9) to 4.6% (95% CI 4.1 to 5.0), low vulnerability populations saw an increase from 4.2% (95% CI 3.7 to 4.7) to 5.4% (95% CI 4.8 to 6.0), while populations with little to no vulnerability rose from 4.2% (95% CI 3.6 to 4.8) to 5.2% (95% CI 4.5 to 6.0). Medium-vulnerability populations showed consistent rates of 4.8% (95% CI 4.4 to 5.3). Employed individuals generally had significantly lower prevalence rates than the unemployed, with a gap widening from 1.7% (95% CI 1.5 to 2.0) in 2019 to 1.9% (95% CI 1.7 to 2.2) in 2022, versus 9.9% (95% CI 9.2 to 10.5) to 10.3% (95% CI 9.7 to 11.0) for the unemployed. Veterans had significantly higher prevalence rates than non-veterans, though it decreased from 13.4% (95% CI 12.1 to 14.8) in 2019 to 12.6% (95% CI 11.2 to 14.1) in 2022, still higher than the 3.8% (95% CI 3.6 to 4.1) to 4.4% (95% CI 4.1 to 4.6) for non-veterans. Foreign-born individuals had prevalence rates of 3.6% (95% CI 3.0 to 4.2) in 2019 and 3.7% (95% CI 3.1 to 4.4) in 2022, which were consistently lower compared to U.S.-born individuals [4.9% (95% CI 4.6 to 5.2) to 5.3% (95% CI 5.0 to 5.6)] with negligible positive trends evident. Angina pectoris Prevalence of angina pectoris by gender and age In the U.S., the prevalence of AP was approximately 1.7% (95% CI 1.5 to 1.9) in 2019 with a nonsignificant change to 1.6% (95% CI 1.5 to 1.8) in 2022 (APC: −1.8%; 95% CI −12.2–10.2%). Males witnessed an increase from 1.7% (95% CI 1.5 to 2.0) in 2019 to 1.9% (95% CI 1.7 to 2.2) in 2022, while female prevalence ranged from 1.6% (95% CI 1.4 to 1.9) in 2019 to 1.4% (95% CI 1.2 to 1.6) in 2022. Both genders had nonsignificant changes on analysis (male APC: 4.0%, 95% CI −5.8–15.0% vs. female APC: −3.9%, 95% CI −18.0–12.9%). AP prevalence increased significantly with age, peaking at 5.7% (95% CI 4.8 to 6.7) for those 75 and older in 2019, and slightly decreasing to 4.9% (95% CI 4.1 to 5.8) in 2022. This was still significantly higher than the prevalence of AP in the 18–44 age group, which remained stable from 0.5% (95% CI 0.3 to 0.6) in 2019 to 0.4% (95% CI 0.2 to 0.5) in 2022 (Table 2; Figs. 5 and 6, Supplementary Table 1). Prevalence of myocardial infarction for adults 18 and over in the United States 2019–2022 Annual percentage change of myocardial infarction for adults 18 and over in the United States 2019–2022 Prevalence of angina pectoris by race White adults witnessed the highest prevalence rate at 1.8% (95% CI 1.6 to 2.0) in both 2019 and 2022. Other analyzed races showed considerable variations in rates. Black or African Americans showed a decrease from 1.4% (95% CI 1.0 to 1.9) in 2019 to 1.1% (95% CI 0.8 to 1.6) in 2022. The Hispanic or Latino population showed a decrease from 1.5% (95% CI 1.1 to 2.1) to 1.2% (95% CI 0.9 to 1.7) over the same period. The Asian population witnessed a slight increase in AP prevalence from 1.1% (95% CI 0.6 to 1.7) in 2019 to 1.4% (95% CI 0.8 to 2.2) in 2022. Prevalence of angina pectoris by geography AP prevalence varied by MSA, with the highest prevalence observed in non-MSA areas, decreasing from 2.9% (95% CI 2.3 to 3.6) in 2019 to 2.7% (95% CI 2.0 to 3.5) in 2022. This was followed by small MSAs, which remained stable at 1.7% (95% CI 1.4 to 2.0) across the years analyzed. The lowest percentages were evident in large MSAs, which showed a negligible decline from 1.4% (95% CI 1.2 to 1.6) to 1.3% (95% CI 1.1 to 1.5) over the study period. Prevalence rates showed considerable variation when stratified by region. The Northeast showed a decreasing trend from 1.9% (95% CI 1.5 to 2.4) in 2019 to 1.6% (95% CI 1.2 to 2.0) in 2022. The South remained at 1.8% (95% CI 1.5 to 2.1), while the Midwest and West both remained consistent at 1.5% (95% CI 1.2 to 1.9). Prevalence of angina pectoris by socio-vulnerability, employment and veteran status Categorizing prevalence according to social vulnerability revealed comparable rates across groups. Medium social vulnerability populations had consistent rates of 1.7% (95% CI 1.4 to 2.0). Most notably, patients with high social vulnerability showed a decrease from 2.1% (95% CI 1.7 to 2.6) to 1.5% (95% CI 1.3 to 1.9), while those with low vulnerability increased from 1.5% (95% CI 1.2 to 1.8) to 1.7% (95% CI 1.4 to 2.1), and those with little to no vulnerability rose from 1.3% (95% CI 1.0 to 1.6) to 1.7% (95% CI 1.3 to 2.1). Employed individuals generally had significantly lower prevalence rates than the unemployed, with stable rates of 0.6% (95% CI 0.5 to 0.8) and 3.4% (95% CI 3.0 to 3.9), respectively, observed across the study period. Veterans had nearly triple the rates of non-veterans, increasing from 3.1% (95% CI 2.5 to 3.9) in 2019 to 4.0% (95% CI 3.2 to 5.0) in 2022, compared to stable rates of 1.5% (95% CI 1.4 to 1.7) among non-veterans. Additionally, prevalence rates for U.S.-born individuals increased slightly from 1.7% (95% CI 1.5 to 1.9) in 2019 to 1.8% (95% CI 1.6 to 2.0) in 2022. These remained consistently higher than those of foreign-born individuals, who reported a slight fall from 1.4% (95% CI 1.0 to 1.9) in 2019 to 1.2% (95% CI 0.9 to 1.6) in 2022. Myocardial infarction Prevalence of myocardial infarction by gender and age The prevalence of MI among U.S. adults decreased from 3.1% (95% CI 2.9 to 3.4) in 2019 to a stable 3.0% (95% CI 2.8 to 3.2) in 2020, with annual trend analysis giving nonsignificant results (APC: −0.9789%; 95% CI −2.4603–0.5460%). Males showed a higher MI prevalence than females, remaining stable at around 4.1% (95% CI 3.8 to 4.5) in 2019 and 2022 (APC: 0.2472%; 95% CI −0.9116–1.3968%), while female prevalence was lower and decreased significantly from 2.2% (95% CI 2.0 to 2.5) in 2019 to 1.8% (95% CI 1.6 to 2.1) in 2022 (APC: −6.3008%; 95% CI −9.2140% to −3.2709%). MI prevalence significantly increased with age, peaking at 11.6% (95% CI 10.5 to 12.9) for those 75 and older in 2019, falling to 9.9% (95% CI 8.7 to 11.2) in 2022. The 18–44-year age group had a substantially lower incidence of MI, showing little variation from 0.3% (95% CI 0.2 to 0.5) to 0.4% (95% CI 0.2 to 0.5) across the study period (l ;Figs. 7 and 8, Supplementary Table 1). Prevalence of angina pectoris for adults 18 and over in the United States 2019–2022 Annual percentage change of angina pectoris for adults 18 and over in the United States 2019–2022 Prevalence of myocardial infarction by race White adults had the highest incidence of MI when stratifying by race, showing a consistent fall from 3.6% (95% CI 3.3 to 3.9) in 2019 to 3.3% (95% CI 3.0 to 3.6) in 2022. They were followed by Black or African Americans, who also showed a decreasing trend from 2.7% (95% CI 2.1 to 3.3) in 2019 to 2.5% (95% CI 2.0 to 3.1) in 2022. Hispanics showed increases in prevalence from 1.4% (95% CI 1.1 to 1.8) to 1.6% (95% CI 1.2 to 2.1). Asians had the lowest rates and notably saw an uptick from 0.9% (95% CI 0.4 to 1.6) in 2019 to 1.8% (95% CI 1.1 to 2.8) in 2022. Prevalence of myocardial infarction by socio-vulnerability, employment and veteran status MI prevalence varied by MSA, with non-MSA areas showing a higher prevalence, followed by Small MSAs and then Large MSAs. Non-MSAs saw a small decrease from 4.9% (95% CI 4.2 to 5.7) in 2019 to 4.6% (95% CI 3.9 to 5.4) in 2022. Similar trends of negligible fall in rates were also seen in small MSAs, from 3.4% (95% CI 3.0 to 3.8) in 2019 to 3.1% (95% CI 2.7 to 3.6) in 2022. Rates showed little variation, remaining stable at 2.5% (95% CI 2.3 to 2.8) throughout the study period for Large MSAs. When stratifying according to census regions, the South consistently reported the highest incidence of MI and showed very little change from 3.4% (95% CI 3.1 to 3.8) to 3.3% (95% CI 2.9 to 3.7). The Midwest followed close behind, with rates varying from 2.6% (95% CI 2.1 to 3.0) to 2.5% (95% CI 2.1 to 3.0) across the study period. The Northeast showed a notable fall in incidence from 3.1% (95% CI 2.6 to 3.7) to 2.6% (95% CI 2.2 to 3.2). Lastly, the West had the lowest rates of any census region, with rates remaining constant between 2.6% (95% CI 2.1 to 3.0) and 2.5% (95% CI 2.1 to 3.0). Prevalence of myocardial infarction by socio-vulnerability, employment and veteran status Variations were noted when patients were stratified according to social vulnerability. However, patients with no [2.7% (95% CI 2.3 to 3.2) to 3.2% (95% CI 2.7 to 3.9)] and low [2.9% (95% CI 2.5 to 3.3) to 3.3% (95% CI 2.9 to 3.9)] social vulnerability showed an increasing trend, while those with medium [3.3% (95% CI 2.9 to 3.7) to 2.9% (95% CI 2.5 to 3.4)] and high [3.5% (95% CI 3.0 to 4.1) to 2.6% (95% CI 2.3 to 3.0)] social vulnerability showed a decreasing trend. Employed individuals generally had lower prevalence rates stable at 1.2% (95% CI 1.1 to 1.5) in 2020–2022, versus prevalence rates of a lowering trend at 6.6% (95% CI 6.1 to 7.2) in 2019 to 5.9% (95% CI 5.4 to 6.5) in 2022 for the unemployed. Veterans had significantly higher prevalence rates than non-veterans, showing a downward trend from 9.5% (95% CI 8.3 to 10.8) in 2019 to 8.4% (95% CI 7.2 to 9.7) in 2022, with non-veterans showing little variation from 2.6% (95% CI 2.4 to 2.8) to 2.5% (95% CI 2.3 to 2.7) from 2019 to 2022. Those born in the U.S. had nearly triple the rates of MI, from 3.5% (95% CI 3.2 to 3.7) in 2019 to 3.2% (95% CI 3.0 to 3.5) in 2022, compared to 1.6% (95% CI 1.2 to 2.0) to 1.8% (95% CI 1.4 to 2.3) for foreign-born individuals. Discussion In this retrospective NHIS database analysis, the authors demonstrated that patients aged ≥ 75 years had a consistently high prevalence of each of the four circulatory diseases, with HTN being the most prevalent during the study period. Compared to females, males had a higher prevalence of HTN, CHD, MI, and AP, however, yearly trends for these diseases varied. Whites had the highest prevalence of CHD, MI, and AP among the races; however, Blacks or African Americans exhibited the highest prevalence of HTN. In addition to the geographic variations, the high-risk groups also included veterans and unemployed individuals [15]. The rise in the prevalence of circulatory diseases during the period 2019–2022 can be explained by several factors. Studies have demonstrated that COVID-19 infection could trigger new cardiovascular events, such as thromboembolism, transient ischemic attack, stroke, heart failure and arrhythmias [16]. Individuals with pre-existing CVD were more likely to experience severe COVID-19 complications, hospitalization, and death. Further, pandemic-related stressors (job loss, social isolation, grief) likely worsened mental health and behavioral risk factors for CVD. This resulted in increased rates of smoking, unhealthy diet, sedentary behavior and psychological distress- all linked to cardiovascular risk [17]. Recent data has shown that after nearly a decade of decline in age-adjusted mortality rates for cardiovascular disease (CVD) between 2010 and 2019, a subsequent increase in these rates has been observed from 2019 to 2022 [6]. This rise was more pronounced among racial and ethnic minorities, and lower socioeconomic groups, reflecting disparities in healthcare access and social determinants of health. The pre-pandemic risk factors of circulatory diseases and their trends may have been exacerbated by the pandemic-related disruptions in lifestyle, along with the increase in circulatory disease-related mortality rates among adults aged 55–64 years [18, 19]. The pandemic exacerbated the disproportionate burden on vulnerable groups including racial and ethnic minorities, low-income populations, and those in under-resourced communities. Notably, Hispanics and non-Hispanic Blacks faced a disproportionate burden of COVID-19 and circulatory diseases due to structural racism in healthcare [20]. The COVID-19 pandemic also magnified the existing health disparities in the delivery of healthcare services for minorities, increasing the population-level burden of circulatory diseases in several locations across the country [21]. The pandemic caused widespread interruptions in chronic disease management due to missed appointments, routine screening and reduced access to medications due to economic strain or supply disruptions. Many people in vulnerable groups delayed or avoided emergency care due to fear of infection or cost leading to late presentations of heart attacks or strokes. Preventive care (like blood pressure checks or lipid screenings) also declined significantly, especially in underserved communities. Our study noted a consistently higher prevalence of circulatory diseases among males compared to females with significant increases in the prevalence of HTN, CHD and AP across the study period. This is consistent with the higher prevalence noted for cardiovascular risk in males compared to females, predominantly among non-Hispanic Blacks during the period 2001–2020 [22]. The relatively lower cardiovascular disease risk burden among females can be explained by the adoption of primary prevention strategies, including healthy lifestyle behaviors and the utilization of medications [23]. Analysis of U.S. adult population data from 2013 to 2018 indicated that the prevalence of HTN is higher and blood pressure control rates are lower in Blacks. The study also highlighted vulnerabilities and disparities in the prevalence of HTN and blood pressure control in Asian Americans and Hispanics [24]. The prevalence rates may have a potential association with greater lifetime discrimination and higher stress levels, however, the strength of the correlation between incident HTN and lifetime discrimination among African Americans is stronger for women compared to men [25]. The differences in the prevalence of circulatory diseases and the relevant risk factors call for targeted public health interventions for promoting health equity and countering disease burden in the US. Our findings align with previous studies indicating that non-Hispanic Black individuals consistently exhibit the highest prevalence of hypertension, whereas non-Hispanic White individuals show the highest prevalence of CHD, MI, and AP. These observations can be explained by differences in genetic predisposition, earlier onset and more severe HTN in Black populations, chronic stress (due to systemic racism, socioeconomic disadvantage, and psychosocial stressors (e.g., job insecurity, discrimination), chronic activation of stress pathways may drive up blood pressure and environmental exposures (i.e., neighborhood-level factors like limited access to fresh food, green space, or safe areas for exercise) also contribute [26, 27]. However, the higher rates of CHD among Whites may be explained by better access to care resulting in more diagnoses. Whites tend to have better access to primary care and diagnostic services including stress testing, leading to higher detection rates of CHD, MI, and angina. Non-Hispanic Whites also tend to be older—age is a strong risk factor for CHD and MI. Further, survivorship bias (i.e., White individuals may survive initial cardiovascular insults at higher rates, which increases the chance of being diagnosed with chronic coronary conditions e.g., angina) and different patterns of risk factor clustering (i.e., while hypertension is more common in Black populations, conditions like dyslipidemia, obesity, and metabolic syndrome may cluster differently in White populations, influencing the expression of CHD) may pay a role [28, 29]. According to the findings of our study, veterans have a greater prevalence of circulatory diseases compared to non-veterans during 2019–2022. Corresponding to these findings, veterans are at a greater risk of developing new-onset heart disease compared to non-veterans, regardless of depressive symptoms, socioeconomic status, comorbidities, and health behaviors. The higher rates of cardiovascular diseases among veterans can partially be explained by a higher prevalence of depression and post-traumatic stress disorder in this population [30, 31]. The significant state-level differences in the prevalence of poor cardiovascular health can be explained by the differences in the social and geographic determinants of circulatory diseases in specific geographical regions [32]. Consistent with the findings of our study, southern states of the US exhibit clustering of higher rates of poor cardiovascular health and greater cardiovascular disease mortality, notably for minorities and low socioeconomic groups [32, 33]. The southern region of the country also exhibits relatively higher social vulnerability and greater disease prevalence in the context of social disadvantages [34]. Our findings indicate that populations with high socioeconomic vulnerability generally exhibit a decrease in circulatory disease prevalence. This trend appears counterintuitive given the known health risks faced by these groups. This could be explained by several factors such as Medicaid expansion, community health centers, and local outreach programs may have improved preventive care, blood pressure monitoring, and access to medications in underserved areas. High-risk populations often become focus areas for public health campaigns (e.g., for hypertension, smoking cessation, or dietary education), which can yield measurable impacts over time. Some lower-income communities have started shifting behaviors due to targeted nutrition assistance programs (like SNAP-Ed) or community-based initiatives like urban gardens or exercise programs. Underdiagnosis may also play a role: people in vulnerable populations might be less likely to seek care or get diagnosed formally, which could artificially lower prevalence in recorded data. Demographic shifts, such as the outmigration of older or sicker individuals, or the influx of younger, healthier populations into these areas, could lower disease prevalence. In very high-vulnerability areas, early mortality from other causes (like accidents, violence, or infectious disease) could mean fewer people live long enough to develop chronic circulatory conditions. While this study provides critical insights into cardiovascular disease trends within the United States, extrapolating these findings to other countries must be done with caution. Significant regional variation exists in the prevalence, risk factors, management strategies, and outcomes of cardiovascular diseases globally. For example, the PURE study, which enrolled individuals from 21 countries of varying income levels, demonstrated that over 80% of CVD burden occurs in low- and middle-income countries (LMICs), where risk factor patterns and healthcare access differ markedly from high-income countries like the U.S [35]. Additionally, INTERHEART, a global case-control study, showed variation in modifiable risk factors’ population-attributable risks across geographic regions [36]. The Global Burden of Disease (GBD) 2019 data further confirms that ischemic heart disease remains the leading cause of death globally but disproportionately affects regions with fewer health resources and differing risk profiles [37]. In this retrospective analysis of the NHIS database, the authors highlighted a critical public health issue, which may pave the way for future research and interventions focused on cardiovascular health in the US. Our study emphasizes the need for tailored and targeted interventions, addressing specific risk factors for different high-risk groups. While our study has focused on different demographics, future studies may take into account the underlying social determinants of health that contribute to circulatory disease risk. Addressing factors including poverty, access to healthcare, social support systems, and education may have a significant impact on reducing the disease burden. Lastly, the findings of this study and other studies in the literature may serve as a nidus for advancements in telemedicine and wearable technology so as to improve access to preventive care strategies. Limitations While the authors provided a comprehensive analysis of prevalence trends and disparities of four circulatory diseases among the US adult population during 2019–2022, this study has several limitations. First, the observational and retrospective nature of data acquisition does not permit the identification of the causality of the prevalence of circulatory diseases in the country. Second, our study and the NHIS database do not take into account the prevalence of undiagnosed circulatory diseases in the country. Third, a substantial proportion of circulatory diseases may be a part of the long-term COVID-19 sequelae. Additionally, the data collection methods employed during the COVID-19 pandemic may not provide accurate estimates of the disease prevalence in light of the established social, geographic, demographic, and biological factors. Fourth, the differences in dietary patterns, lifestyle behaviors, demographics, and healthcare systems limit the generalizability of the analysis findings for other regions of the world. Fifth, although Joinpoint regression is traditionally applied to longer time series, it was employed here to provide a descriptive analysis of short-term trends in circulatory disease prevalence from 2019 to 2022. Results should be interpreted with caution, acknowledging the limited timeframe. A key limitation of this study is the potential overlap between coronary artery disease, angina pectoris, and myocardial infarction, all of which fall under the broader category of coronary heart disease (CHD). While we analyzed these conditions separately to capture distinct prevalence patterns, this approach may lead to partial misclassification or double-counting in individuals with multiple diagnoses. Future studies using clinical or administrative data sources may help better delineate these subgroups. Another limitation of this study is the reliance on self-reported data from the NHIS, which may introduce recall bias and underreporting. Conditions such as hypertension, angina, MI, and CHD may be underdiagnosed or unrecognized, particularly among populations with limited access to healthcare. Consequently, the true prevalence may be underestimated, and disparities could be either masked or exaggerated depending on awareness and reporting accuracy across subgroups. Recall bias—where participants may forget or inaccurately report previous diagnoses—can particularly affect older adults or individuals with limited health literacy. Additionally, diagnostic bias stemming from variability in healthcare access, provider practices, and diagnostic thresholds may influence the accuracy and comparability of reported prevalence rates across subgroups. These factors may result in either underestimation or overestimation of true disease prevalence, and should be considered when interpreting the findings. We were unable to adjust for key cardiovascular risk factors like diabetes, obesity, tobacco use, and socioeconomic status, which likely influence disease prevalence. Future research with multivariable models is needed to better understand the independent effects of these factors on cardiovascular disparities. The limited number of time points in our dataset may preclude robust analysis of trend changes, such as those evaluated by Joinpoint regression, which generally requires a minimum of five to six data points to detect inflection points. Nevertheless, this manuscript provides valuable early insights into temporal patterns using real-world data. Despite the constraint in the number of time points, the study contributes important preliminary evidence that can guide future longitudinal research with more frequent data collection intervals. By highlighting potential shifts within a constrained but recent time window, our analysis offers timely insights that can inform clinical and public health priorities and serve as a foundation for ongoing longitudinal surveillance. Last, we were not able to conduct sensitivity analysis or subgroup stratification by COVID- exposure or related disruptions (e.g., healthcare access loss) limiting the attribution of trend changes to the pandemic period. Conclusion This study investigated the trends and disparities in circulatory diseases including AP, CHD, MI, and HTN among US adults during 2019–2022. Our findings highlight concerning trends in the country regarding the prevalence and disparities of the stated circulatory diseases. While all the circulatory diseases demonstrated a concerning rise in prevalence, HTN remained the most prevalent disease. Males consistently exhibited higher prevalence than females across all diseases. While Blacks had the highest prevalence of HTN, Whites had the highest prevalence of CHD, AP, and MI. Geographically, the South had the highest prevalence of most circulatory diseases. These findings underscore the urgency for targeted interventions. Public health strategies should prioritize high-risk groups like males, older adults, and racial minorities residing in high-burden regions. Tailoring interventions based on gender, race, and socioeconomic factors is crucial to effectively combat this public health crisis and promote cardiovascular health for all US adults. Supplementary Information Supplementary Material 1 Acknowledgements None to declare. Author contributions Yasmin F, Mooed A participated in the conceptualization, data curation, and writing of the original draft. Rahman HAU, Fahim MAA, Salman A, Shaharyar M participated in the investigation, methodology, project administration, resources, and writing of the original draft. Asghar MS, Alraies MC participated in the supervision, validation, visualization, and writing – review & editing. Funding None to declare. Data availability No datasets were generated or analysed during the current study. Declarations Human Ethics and Consent to Participate approval Not applicable. Consent to participate Not applicable. Consent to publish Not applicable. Competing interests The authors declare no competing interests. Clinical trial number Not applicable. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement No datasets were generated or analysed during the current study.